R Squared’s Arcus Biosciences RCUS Stock Holding History

R Squared’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,720	Closed	-$25.6K	–	1214
2024 Q4	$25.6K	Buy	+1,720	New	+$28.1K	0.02%	771

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

R Squared's RCUS Position: Q1 2025 in Review

R Squared sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 1,720 shares — an estimated $25.6K sold.

R Squared first reported a position in RCUS in Q4 2024 and held it in 1 quarter. The position peaked at $25.6K in Q4 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

R Squared reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,720 Arcus Biosciences shares in Q1 2025, an estimated $25.6K.
R Squared first reported a position in Arcus Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Arcus Biosciences position peaked at $25.6K in Q4 2024.
186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.